No price history available.

Not enough data to calculate KvantraRank

Based on consensus from external analysts. Not Kvantra's opinion.

Pure Biologics Spólka Akcyjna operates as a biopharmaceutical enterprise, concentrating its efforts on the discovery and development of novel biological pharmaceuticals and targeted, non-systemic treatments. The company's key therapeutic interests span immuno-oncology, various autoimmune conditions, and rare diseases. Its capabilities encompass the entire process for antibodies and aptamers, from their initial creation and purification to detailed analysis and characterization. Additionally, Pure Biologics is skilled in the design, development, and rigorous validation of diagnostic and research assays, while also advancing technology platforms for the precise selection of active therapeutic molecules. A significant offering is PureApta, a adaptable platform engineered for the in vitro selection of modified aptamers, suitable for both medical treatment and diagnostic applications. The firm is also actively pursuing the development of localized therapies aimed at assisting individuals afflicted by neurological autoimmune disorders, including conditions like neuromyelitis optica and myasthenia gravis. Founded in 2010, Pure Biologics Spólka Akcyjna is headquartered in Wroclaw, Poland.

• Tempest Therapeutics, Inc.
• Nuformix plc
• Mustang Bio, Inc.
• Alaunos Therapeutics, Inc.
• CollPlant Biotechnologies Ltd.
• Galmed Pharmaceuticals Ltd.
• Mosaic ImmunoEngineering Inc.
• 2cureX AB (publ)